0000073290 2025-06-01 2026-05-31 0000073290 2025-11-28 0000073290 2026-09-28 iso4217:USD shares iso4217:USD shares true FY 0000073290 10-K/A true 2026-05-31 --05-31 2026 false 001-37863 BIOMERICA, INC. DE 95-2645573 17571 Von Karman Avenue Irvine CA 92614 (949) 645-2111 Common Stock, par value $0.08 BMRA NASDAQ No No Yes Yes Non-accelerated Filer true false false false false 6600000 0.08 4598968 This Amendment No. 1 on Form 10-K/A (this “Amendment No. 1”) amends the Annual Report on Form 10-K for the fiscal year ended May 31, 2026 (the “2026 Annual Report”), originally filed by Biomerica, Inc. with the Securities and Exchange Commission (the “SEC”) on August 31, 2026. References throughout this Amendment No. 1 to “Biomerica, Inc.”, “Biomerica”, “we”, “us”, “our”, or the “Company” refer to Biomerica, Inc. and its subsidiaries, taken as a whole, unless the context otherwise indicates. We are filing this Amendment No. 1 pursuant to General Instruction G(3) of Form 10-K, as we do not intend to file a definitive proxy statement for our 2026 Annual Meeting of stockholders (the “Annual Meeting”) within 120 days of the end of our fiscal year ended May 31, 2026. Accordingly, this Amendment No. 1 is being filed solely to:     ● amend and restate Part III, Items 10 (Directors, Executive Officers and Corporate Governance), 11 (Executive Compensation), 12 (Security Ownership of Certain Beneficial Owners and Management Related Stockholder Matters), 13 (Certain Relationships and Related Transactions, and Director Independence) and 14 (Principal Accountant Fees and Services) of our 2026 Annual Report, in their entirety as set forth herein; and         ● file new certifications of our principal executive officer and principal financial officer as exhibits to this Amendment No. 1 under Item 15 of Part IV hereof pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).   Because no financial statements are included in this Amendment No. 1, and this Amendment No. 1 does not contain or amend any disclosure with respect to Items 307 or 308 of Regulation S-K, paragraphs 3, 4 and 5 of the certifications have been omitted. Additionally, new certifications under Section 906 of the Sarbanes-Oxley Act of 2002 are not being furnished with this Amendment No. 1.   Except as set forth above, no other Items of our 2026 Annual Report have been amended or revised in this Amendment No. 1, and all such other Items shall be as set forth in such 2026 Annual Report. Accordingly, this Amendment No. 1 should be read in conjunction with the 2026 Annual Report and our other filings with the SEC. Certain capitalized terms used and not otherwise defined in this Amendment No. 1 have the meanings given to them in the 2026 Annual Report.   true